Pancreatic Cancer Research

ResearcherUniversity of PisaActive in the last 2 years

Francesco Novelli

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-6259-5666; OpenAlex author ID A5040743234. Sources: OpenAlex.

Their work

Papers
43 (first author 1, last author 15)
Trials
0
Grants
0
Labs led
1
Collaborators
96
Papers, trials and grants by year

2011: 2 papers · 2012: 3 papers · 2013: 6 papers · 2014: 1 paper · 2015: 2 papers · 2016: 5 papers · 2017: 2 papers · 2018: 4 papers · 2019: 2 papers · 2020: 5 papers · 2021: 2 papers · 2022: 1 paper · 2023: 3 papers · 2024: 3 papers · 2025: 1 paper · 2026: 1 paper

Papers 43

  1. The H63D Polymorphism in the HFE Gene Promotes Aggressive Disease Phenotypes in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-25-4154↗
  2. The absence of IL17A favours cytotoxic cell function and improves antigen-specific immunotherapies in pancreatic adenocarcinoma. Co-author DOI 10.1002/ctm2.70442↗
  3. PI3Kγ inhibition combined with DNA vaccination unleashes a B-cell-dependent antitumor immunity that hampers pancreatic cancer. Last author DOI 10.1186/s13046-024-03080-1↗
  4. In pancreatic cancer patients, chemotherapy reshapes the gene expression profile and antigen receptor repertoire of T lymphocytes and enhances their effector r… Last author DOI 10.3389/fimmu.2024.1427424↗
  5. Fighting Pancreatic Cancer with a Vaccine-Based Winning Combination: Hope or Reality? Co-author DOI 10.3390/cells13181558↗
  6. Circulating autoantibodies to alpha-enolase (ENO1) and far upstream element-binding protein 1 (FUBP1) are negative prognostic factors for pancreatic cancer pat… Last author DOI 10.1007/s10238-023-01236-5↗
  7. IL-1β+ macrophages fuel pathogenic inflammation in pancreatic cancer. Co-author DOI 10.1038/s41586-023-06685-2↗
  8. Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2021-325117↗
  9. Docking Protein p130Cas Regulates Acinar to Ductal Metaplasia During Pancreatic Adenocarcinoma Development and Pancreatitis. Co-author DOI 10.1053/j.gastro.2021.12.242↗
  10. IL17A critically shapes the transcriptional program of fibroblasts in pancreatic cancer and switches on their protumorigenic functions. Co-author DOI 10.1073/pnas.2020395118↗
  11. The Glycolytic Pathway as a Target for Novel Onco-Immunology Therapies in Pancreatic Cancer. Last author DOI 10.3390/molecules26061642↗
  12. In pancreatic cancer, chemotherapy increases antitumor responses to tumor-associated antigens and potentiates DNA vaccination. Last author DOI 10.1136/jitc-2020-001071↗
  13. Metabolome of Pancreatic Juice Delineates Distinct Clinical Profiles of Pancreatic Cancer and Reveals a Link between Glucose Metabolism and PD-1+ Cells. Co-author DOI 10.1158/2326-6066.cir-19-0403↗
  14. Diabetes promotes invasive pancreatic cancer by increasing systemic and tumour carbonyl stress in Kras G12D/+ mice. Co-author DOI 10.1186/s13046-020-01665-0↗
  15. The dark side of immunotherapy: pancreatic cancer. Co-author DOI 10.20517/cdr.2020.13↗
  16. Immune-Complexome Analysis Identifies Immunoglobulin-Bound Biomarkers That Predict the Response to Chemotherapy of Pancreatic Cancer Patients. Last author DOI 10.3390/cancers12030746↗
  17. Stromal protein βig-h3 reprogrammes tumour microenvironment in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2018-317570↗
  18. Integrative Analysis of Novel Metabolic Subtypes in Pancreatic Cancer Fosters New Prognostic Biomarkers. Co-author DOI 10.3389/fonc.2019.00115↗
  19. The advanced glycation end-product Nϵ -carboxymethyllysine promotes progression of pancreatic cancer: implications for diabetes-associated risk and its prevent… Co-author DOI 10.1002/path.5072↗
  20. Depletion of tumor-associated macrophages switches the epigenetic profile of pancreatic cancer infiltrating T cells and restores their anti-tumor phenotype. Co-author DOI 10.1080/2162402x.2017.1393596↗
  21. Soluble stroma-related biomarkers of pancreatic cancer. Co-author DOI 10.15252/emmm.201708741↗
  22. Next Generation Immunotherapy for Pancreatic Cancer: DNA Vaccination is Seeking New Combo Partners. Last author DOI 10.3390/cancers10020051↗
  23. Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis. Last author DOI 10.1186/s13045-016-0385-8↗
  24. Endogenous glutamine decrease is associated with pancreatic cancer progression. Last author DOI 10.18632/oncotarget.20545↗
  25. A bioluminescent mouse model of proliferation to highlight early stages of pancreatic cancer: A suitable tool for preclinical studies. Co-author DOI 10.1016/j.aanat.2015.11.010↗
  26. Intra-tumoral IFN-γ-producing Th22 cells correlate with TNM staging and the worst outcomes in pancreatic cancer. Co-author DOI 10.1042/cs20150437↗
  27. Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma. Co-author DOI 10.1080/2162402x.2015.1085147↗
  28. Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression. Co-author DOI 10.1158/2159-8290.cd-15-1346↗
  29. Peripheral ENO1-specific T cells mirror the intratumoral immune response and their presence is a potential prognostic factor for pancreatic adenocarcinoma. Co-author DOI 10.3892/ijo.2016.3524↗
  30. Phosphorylated alpha-enolase induces autoantibodies in HLA-DR8 pancreatic cancer patients and triggers HLA-DR8 restricted T-cell activation. Last author DOI 10.1016/j.imlet.2015.06.008↗
  31. Targeting of surface alpha-enolase inhibits the invasiveness of pancreatic cancer cells. Last author DOI 10.18632/oncotarget.3572↗
  32. Class II transactivator-induced MHC class II expression in pancreatic cancer cells leads to tumor rejection and a specific antitumor memory response. Last author DOI 10.1097/mpa.0000000000000160↗
  33. Mass spectrometric analysis reveals O-methylation of pyruvate kinase from pancreatic cancer cells. Co-author DOI 10.1007/s00216-013-6880-7↗
  34. Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell … Co-author DOI 10.1007/s00262-013-1429-3↗
  35. Towards pancreatic cancer diagnosis using EIS biochips. Co-author DOI 10.1039/c2lc41127j↗
  36. Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer. Last author DOI 10.1053/j.gastro.2013.01.020↗
  37. Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models. Last author DOI 10.1186/1756-8722-6-67↗
  38. A self antigen reopens the games in pancreatic cancer. First author DOI 10.4161/onci.24384↗
  39. MS analysis reveals O-methylation of L-lactate dehydrogenase from pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1002/elps.201200017↗
  40. Proteomic analysis reveals Warburg effect and anomalous metabolism of glutamine in pancreatic cancer cells. Co-author DOI 10.1021/pr2009274↗
  41. Molecular and genetic bases of pancreatic cancer. Co-author DOI 10.2174/138945012800564077↗
  42. Circulating autoantibodies to phosphorylated α-enolase are a hallmark of pancreatic cancer. Last author DOI 10.1021/pr100213b↗
  43. Proteomic analysis of pancreatic ductal adenocarcinoma cells reveals metabolic alterations. Co-author DOI 10.1021/pr101179t↗

Closest collaborators

The 25 strongest of 96 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Paola Cappello · 32 shared papers, 2011–2026 · strength 2.89
  2. Claudia Curcio · 10 shared papers, 2017–2025 · strength 1.50
  3. Silvia Brugiapaglia · 8 shared papers, 2020–2025 · strength 1.39
  4. Cecilia Roux · 6 shared papers, 2017–2025 · strength 0.78
  5. Gianluca Mucciolo · 4 shared papers, 2020–2025 · strength 0.62
  6. Michela Capello · 12 shared papers, 2011–2021 · strength 0.60
  7. Rosella Spadi · 5 shared papers, 2019–2024 · strength 0.59
  8. Francesca Cordero · 4 shared papers, 2019–2024 · strength 0.46
  9. Laura Follia · 4 shared papers, 2019–2021 · strength 0.43
  10. Giorgia Mandili · 5 shared papers, 2013–2020 · strength 0.40
  11. Alessandro Zerbi · 3 shared papers, 2016–2026 · strength 0.35
  12. Aldo Scarpa · 5 shared papers, 2011–2023 · strength 0.35
  13. Claudio Doglioni · 2 shared papers, 2023–2026 · strength 0.34
  14. Massimo Falconi · 2 shared papers, 2023–2026 · strength 0.34
  15. Paola Allavena · 4 shared papers, 2016–2020 · strength 0.29
  16. Andrea Costamagna · 2 shared papers, 2022–2023 · strength 0.27
  17. Elisa Giovannetti · 2 shared papers, 2022–2023 · strength 0.27
  18. Miriam Martini · 2 shared papers, 2022–2023 · strength 0.27
  19. Vincenzo Corbo · 2 shared papers, 2023 · strength 0.25
  20. Lorenzo Piemonti · 5 shared papers, 2011–2023 · strength 0.24
  21. Luisa de Latouliere · 3 shared papers, 2016–2020 · strength 0.24
  22. Stefano Menini · 3 shared papers, 2016–2020 · strength 0.24
  23. Giuseppe Pugliese · 3 shared papers, 2016–2020 · strength 0.24
  24. Giulia Piaggio · 3 shared papers, 2016–2020 · strength 0.24
  25. Judith A. Varner · 2 shared papers, 2016–2024 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.